Northwest Biotherapeutics, Inc.
NWBO
$0.25
$0.00-0.83%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.29% | -41.29% | -33.50% | 10.25% | -28.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.29% | -41.29% | -33.50% | 10.25% | -28.47% |
| Cost of Revenue | -17.49% | 6.08% | 11.47% | 22.51% | 25.81% |
| Gross Profit | 18.20% | -8.58% | -14.00% | -23.11% | -29.88% |
| SG&A Expenses | -1.50% | -2.54% | -2.67% | 11.16% | 11.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.72% | 1.70% | 4.17% | 16.64% | 18.19% |
| Operating Income | 9.91% | -2.78% | -5.17% | -16.79% | -19.82% |
| Income Before Tax | 27.55% | -29.11% | -11.72% | -20.71% | -33.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.19% | -29.11% | -11.72% | -20.71% | -33.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.19% | -29.11% | -11.72% | -20.71% | -33.83% |
| EBIT | 9.91% | -2.78% | -5.17% | -16.79% | -19.82% |
| EBITDA | 10.68% | -2.79% | -5.21% | -17.04% | -19.97% |
| EPS Basic | 37.67% | -7.47% | 6.19% | -2.54% | -15.16% |
| Normalized Basic EPS | 28.01% | 0.29% | 7.61% | -3.45% | -24.03% |
| EPS Diluted | 34.75% | -3.00% | -1.08% | -10.00% | -23.34% |
| Normalized Diluted EPS | 28.01% | 0.29% | 7.61% | -3.45% | -24.03% |
| Average Basic Shares Outstanding | 17.24% | 16.14% | 14.24% | 12.00% | 11.00% |
| Average Diluted Shares Outstanding | 17.24% | 16.14% | 14.24% | 12.00% | 11.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |